Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Breast Cancer
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make…
- Trial name
- NCT00004038
- Testing
- Ad5CMV-p53 gene, chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Cabozantinib for Metastatic Triple Negative BrCa
In this research study, we are looking at the anti-tumor effects of Cabozantinib (XL184) in metastatic breast cancer. Data suggest that MET expression and activation are important for initiation and progression of triple-negative…
- Trial name
- NCT01738438
- Testing
- Cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
HER2-positive Breast Cancer, Recurrent Breast Cancer
PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer
This phase I trial studies the side effects of positron emission tomography (PET)/computed tomography (CT) in evaluating response to chemotherapy in patients with breast cancer.
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT01712815
- Testing
- laboratory biomarker analysis, pharmacological study, questionnaire administration
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Southern California
Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma
Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice
This trial studies the impact of the breast cancer pathways program on the patient experience, including decision making and quality of life.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04297384
- Testing
- Informational Intervention, Quality-of-Life Assessment, Survey Administration
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
HER2-positive Breast Cancer
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
The purpose of this study is to evaluate the effectiveness of anti-HER2 therapy plus Fulvestrant or Capecitabine in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+)…
- Trial name
- FAVOR (NCT04337658)
- Testing
- Pertuzumab, Trastuzumab, Fulvestrant
- Where
- 2 sites in China
- Volunteers
- 493 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral vinorelbine can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.
- Trial name
- NCT02768415
- Testing
- Apatinib, Oral Vinorelbine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Breast Cancer, HER2-negative Breast Cancer
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
This will be a single arm, open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC.
- Trial name
- NCT05025735
- Testing
- Dapagliflozin 10Mg Tab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Saint Luke's Health System
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Breast Cancer
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating older women who have stage IV…
- Trial name
- NCT00022152
- Testing
- vinorelbine tartrate
- Where
- 18 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α). In preclinical studies, it demonstrated strong activity against PI3K p110α in vitro and in vivo, and inhibited tumor cell…
- Trial name
- NCT04631835
- Testing
- HS-10352
- Where
- 3 sites in China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive…
- Trial name
- SUMMIT (NCT01953926)
- Testing
- Neratinib, Fulvestrant, Trastuzumab
- Where
- 60 sites in United States, Australia and 11 more
- Volunteers
- 582 people
- Sponsor
- Puma Biotechnology, Inc.
Breast Cancer
ICI 182780 in Treating Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 may fight breast cancer by blocking the activity of estrogen in the tumor cells.
- Trial name
- NCT00012025
- Testing
- fulvestrant
- Where
- 25 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
- Trial name
- NCT01419717
- Testing
- Denosumab
- Where
- 64 sites in Argentina, Austria and 17 more
- Volunteers
- 129 people
- Sponsor
- Amgen
Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic Solid Tumor
- Trial name
- NCT07423117
- Testing
- ITC-6146RO
- Volunteers
- 102 people
- Sponsor
- IntoCell, Inc
Breast Cancer, Bone Metastases
Bone Response in Metastatic Breast Cancer Involving Bones
Primary Objectives: To estimate and compare the sensitivity and specificity of computed tomography (CT), plain radiography (XR), and skeletal scintigraphy (SS) with each other for the assessment of response of bone metastasis in…
- Trial name
- NCT00420433
- Testing
- Skeletal Scintigraphy, Radiography, CT Scan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Triple Negative Breast Cancer Metastatic
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor relapsed following treatment with curative intent for early disease, which must…
- Trial name
- ATRiBRAVE (NCT05582538)
- Testing
- Ceralasertib, Durvalumab, Nab-paclitaxel
- Where
- 6 sites in Italy
- Volunteers
- 37 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Breast Cancer, Colorectal Cancer
Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer
RATIONALE: Collecting information over time about patients' and health care providers' understanding of pain and fatigue and providing education about pain and fatigue management may improve quality of life.
- Conditions
- Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer
- Trial name
- NCT00900835
- Testing
- educational intervention, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 470 people
- Sponsor
- City of Hope Medical Center
Metastatic Breast Cancer
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.
- Trial name
- NCT00634634
- Testing
- Sorafenib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Neoplasm, Antineoplastic Agents
Anlotinib in Metastatic HER2 Negative Breast Cancer
The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.
- Conditions
- Breast Neoplasm, Antineoplastic Agents, Anlotinib
- Trial name
- NCT04002284
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peng Yuan
Stage IA Breast Cancer, Stage IB Breast Cancer
Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy
This pilot clinical trial studies a health education intervention in reducing weight gain in patients with newly diagnosed stage I-IV breast cancer undergoing chemotherapy.
- Conditions
- Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01941784
- Testing
- educational intervention, counseling intervention, telephone-based intervention
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.